Nijmegen-based MedTech company, Plasmacure, raised €6 million in Series A funding to scale globally and advance their PLASOMA cold plasma system for complex wound treatment.
The investment, led by U.S.-based Venture Medical, LLC, aims to support Plasmacure in bringing the PLASOMA device to more patients worldwide and to set a new global standard in wound care.
PLASOMA utilizes cold plasma to accelerate wound healing, demonstrating up to 2.5 times greater effectiveness than standard care by eliminating antibiotic-resistant bacteria and stimulating blood flow and cell regeneration.
The funding will also support Plasmacure's U.S. market entry to address the growing need for advanced wound care solutions as the prevalence of complex wounds rises, impacting quality of life and contributing to significant healthcare costs.